Background: Association between poor control of glycemia and the onset of microvascular complications in type 2 diabetes mellitus (T2DM) patients is a hard issue. However, it seems that the impact of pharmacological treatment is important only in early stages of diabetic nephropathy. We sought to examine whether intensive glycemic control is associated with improvement of clinical Chronic Kidney Disease (CKD) outcomes compared to standard glycemic control.Methods: Meta-analysis of published and unpublished randomized controlled trials (RCT) and post-hoc analysis of RCTs comparing anti-diabetic drugs and/or insulin (intensive control) vs. dietary measures (standard control) for relevant outcomes related to progression of CKD clinically manif...
AIM: The use of sodium glucose co-transporter 2 (SGLT2) inhibitors in patients with type 2 diabetes ...
Background: Large trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce t...
Background Chronic kidney disease is characterised by low estimated glomerular fi ltration rate (eGF...
Producción CientíficaBackground: Association between poor control of glycemia and the onset of micro...
The effect of intensive glucose control on major kidney outcomes in type 2 diabetes remains unclear....
BACKGROUND: Chronic kidney disease is characterised by low estimated glomerular filtration rate (eGF...
Background: Diabetes is the leading cause of end-stage kidney disease (ESKD) around the world. Blood...
Background: Intensive glucose control is understood to prevent complications in adults with type 2 d...
BACKGROUND: Chronic kidney disease is characterised by low estimated glomerular filtration rate (e...
Results of the main Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial indicate that i...
Chronic kidney disease (CKD) and cardiovascular disease share common risk factors such as hypertensi...
AIM: The use of sodium glucose co-transporter 2 (SGLT2) inhibitors in patients with type 2 diabetes ...
Background: Large trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce t...
Background Chronic kidney disease is characterised by low estimated glomerular fi ltration rate (eGF...
Producción CientíficaBackground: Association between poor control of glycemia and the onset of micro...
The effect of intensive glucose control on major kidney outcomes in type 2 diabetes remains unclear....
BACKGROUND: Chronic kidney disease is characterised by low estimated glomerular filtration rate (eGF...
Background: Diabetes is the leading cause of end-stage kidney disease (ESKD) around the world. Blood...
Background: Intensive glucose control is understood to prevent complications in adults with type 2 d...
BACKGROUND: Chronic kidney disease is characterised by low estimated glomerular filtration rate (e...
Results of the main Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial indicate that i...
Chronic kidney disease (CKD) and cardiovascular disease share common risk factors such as hypertensi...
AIM: The use of sodium glucose co-transporter 2 (SGLT2) inhibitors in patients with type 2 diabetes ...
Background: Large trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce t...
Background Chronic kidney disease is characterised by low estimated glomerular fi ltration rate (eGF...